

2024年 著書・論文 P. 1

1 著書	Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma	Kawaguchi T, Yoshio S, Sakamoto Y, Hashida R, Koya S, Hirota K, Nakano D, Yamamura S, Niizeki T, Matsuse H, Torimura T	Prevention and Treatment of Sarcopenia Gianluca Testa 編 MDPI Basel, Switzerland p. 263-274, 2024
2 著書	8 肝動注科学療法	岩本英希	もう迷わない！肝癌薬物療法ナビ 建石良介、山下竜也 編 南江堂 東京 p. 115-122, 2024
3 著書	第3章 びまん性肝疾患における各論 E.アルコール性肝障害	川口 巧	肝生検ガイドンス 日本肝臓学会 編 南江堂 東京 p. 57-61, 2024
4 著書	肝臓専門医テキスト 改訂第4版	川口 巧	肝臓専門医テキスト 改訂第4版 日本肝臓学会 編 南江堂 東京
5 著書	VIII消化器系疾患の診断・治療・ケア 86.急性肝不全昏睡型の管理指針	佐野有哉、天野恵介、桑原礼一郎	救急・集中治療最新ガイドライン2024-'25 土井研人 編 総合医学社 東京 p. 330-331, 2024
6 著書	減量・代謝改造手術のための包括的な肥満症治療ガイドライン2024	川口 巧	減量・代謝改造手術のための包括的な肥満症治療ガイドライン2024 日本肥満症治療学会 編 コンパス出版局 東京 p. ix, 2024
7 著書	V. 大腸 ①.大腸領域の定義と分類 3.炎症性腸疾患の内視鏡分類	鈴木桂悟、吉岡慎一郎	消化器内視鏡ハンドブック 改訂第3版 日本消化器内視鏡学会卒業教育委員会 編 医学図書出版 東京 p. 445-450, 2024

2024年 著書・論文 P. 2

8 著書	第6章 肝硬変になりかけの肝臓が正常に戻る肝炎体操や脂肪肝を改善する腸活など肝臓専門医が教える本当に肝臓にいい生活習慣	川口 巧、栗原 毅、泉 並木	大学教授・肝臓の名医陣が教える禁酒を頑張らなくても肝機能がみるみる強まる食べ方飲み方大全 上野陽之介 編 文響社 東京 p. 114-125, 2024
9 著書	脂肪性肝疾患の新概念 MASLD～No more NAFLD～	川口 巧	糖尿病学2024 門脇 孝、山内敏正 編 診断と治療社 東京 p. 88-94, 2024
10 原著	Efficacy and safety of filgotinib for ulcerative colitis: A real-world multicenter retrospective study in Japan	Akiyama S, Yokoyama K, Yagi S, Shinzaki S, Tsuruta K, Yoshioka S, Sako M, Shimizu H, Kobayashi M, Sakurai T, Nomura K, Shibuya T, Takahara M, Hiraoka S, Sugai K, Yanai S, Yoshida A, Koroku M, Omori T, Saruta M, Matsumoto T, Okamoto R, Tsuchiya K, Fujii T	Alimentary Pharmacology & Therapeutics 59: 1413-1424, 2024
11 原著	Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: A multicenter study in Japan	Tsutsumi T, Kawaguchi T, Fujii H, Kamada Y, Takahashi H, Kawanaka M, Sumida Y, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Ueda S, Aishima S, Nakajima A, Okanoue T	Alimentary Pharmacology & Therapeutics 59: 1559-1570, 2024
12 原著	Socio-economic association of alcohol use disorder and cardiovascular and alcohol-associated liver disease from 2010 to 2019	Danpanichkul P, Chen VL, Chaikunapruk N, Auttapracha T, Kongarin S, Ng CH, Duangsonk K, Muthiah MD, Sukphutanan B, Sim B, Huang DQ, Seko Y, Lee BP, Takahashi H, Nouredin M, Lazarus JV, Diaz LA, Arab JP, Mellinger JL, Liangpunsakul S, Wijarnpreecha K	Alimentary Pharmacology & Therapeutics 60: 340-349, 2024
13 原著	How Does Omitting Additional Surgery After Local Excision Affect the Prognostic Outcome of Patients With High-risk T1 Colorectal Cancer?	Ouchi A, Komori K, Masahiro T, Toriyama K, Kajiwarra Y, Oka S, Fukunaga Y, Hotta K, Ikematsu H, Tsukamoto S, Nagata S, Yamada K, Konno M, Ishihara S, Saitoh Y, Matsuda K, Togashi K, Ishiguro M, Kuwai T, Okuyama T, Ohuchi A, Ohnuma S, Sakamoto K, Sugai T, Katsumata K, Matsushita HO, Nakai K, Uraoka T, Akimoto N, Kobayashi H, Ajioka Y, Sugihara K, Ueno H; Study Group for the JSCCR-T study	Annals of surgery 279: 290-296, 2024

14 原著	Prognosis of biopsy-confirmed MASLD: a sub-analysis of the CLIONE study	Iwaki M, Fujii H, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Clinical and Molecular Hepatology 30: 225-234, 2024
15 原著	A Comparative Analysis of Nursing Care Needs Scores at Discharge and Transfer Among Survivors of Critical COVID-19 and Septic Shock: A Retrospective Observational Study Using Modified Poisson Regression From Japan	Kawabata J, Kuwaki K	Cureus 16: e74032, 2024
16 原著	Efficacy of Atezolizumab Plus Bevacizumab-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma	Moriyama E, Shimose S, Niizeki T, Iwamoto H, Tanaka M, Shirono T, Noda Y, Nakano M, Kuromatsu R, Koga H, Kawaguchi T	Current Oncology 31: 5821-5831, 2024
17 原著	Ex-vivo expanded CD34+ cell transplantation alleviates fibrotic liver injury via innate immune modulation in metabolic dysfunction-associated steatohepatitis mice	Masuda A, Nakamura T, Iwamoto H, Suzuki H, Sakaue T, Tanaka T, Imamura Y, Mori N, Koga H, Kawaguchi T	Cytotherapy 26: 899-909, 2024
18 原著	Sex and Race-Ethnic Disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease: An Analysis of 40,166 Individuals	Fu CE, Teng M, Tung D, Ramadoss V, Ong C, Koh B, Lim WH, Tan DJH, Koh JH, Nah B, Syn N, Tamaki N, Siddiqui MS, Wijarnpreecha K, Ioannou GN, Nakajima A, Nouredin M, Sanyal AJ, Ng CH, Muthiah M	Digestive Diseases and Sciences 69: 3195-3205, 2024
19 原著	Immunoglobulin-like transcript 2 as an impaired anti-tumor cytotoxicity marker of natural killer cells in patients with hepatocellular carcinoma	Sakata T, Yoshio S, Yamazoe T, Mori T, Kakazu E, Aoki Y, Aoyanagi N, Okamoto T, Ito T, Toyoda H, Kawaguchi T, Ono Y, Takahashi Y, Taketomi A, Kanto T	Frontiers in Immunology 15: 1389411, 2024
20 原著	Booster COVID-19 mRNA vaccination ameliorates impaired B-cell but not T-cell responses in older adults	Kometani K, Yorimitsu T, Jo N, Yamaguchi E, Kikuchi O, Fukahori M, Sawada T, Tsujimoto Y, Sunami A, Li M, Ito T, Pretemer Y, Gao Y, Hidaka Y, Yamamoto M, Kaku N, Nakagama Y, Kido Y, Grifoni A, Sette A, Nagao M, Morita S, Nakajima TE, Muto M, Hamazaki Y	Frontiers in Immunology 15: 1455334, 2024

21 原著	Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma	Sakaue T, Koga H, Iwamoto H, Nakamura T, Masuda A, Tanaka T, Suzuki H, Suga H, Hirai S, Hisaka T, Naito Y, Ohta K, Nakamura K, Selvendiran K, Okabe Y, Torimura T, Kawaguchi T	Gastro Hep Advances 3: 761-772, 2024
22 原著	Clinical Characteristics of Steatotic Liver Disease Categories in a Large Cohort of Japanese Health Checkup Participants	Kamada Y, Fujii H, Suzuki Y, Sawada K, Tatsuta M, Maeshiro T, Tobita H, Tsutsumi T, Akahane T, Hasebe C, Kawanaka M, Kessoku T, Eguchi Y, Syokita H, Nakajima A, Kamada T, Yoshiji H, Kawaguchi T, Sakugawa H, Morishita A, Masaki T, Ohmura T, Watanabe T, Yoda Y, Enomoto N, Ono M, Fuyama K, Okada K, Nishimoto N, Ito YM, Takahashi H, Sumida Y; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Gastro Hep Advances 3: 1148-1156, 2024
23 原著	A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis	Hitomi Y, Ueno K, Aiba Y, Nishida N, Kono M, Sugihara M, Kawai Y, Kawashima M, Khor SS, Sugi K, Kouno H, Kohno H, Naganuma A, Iwamoto S, Katsushima S, Furuta K, Nikami T, Mannami T, Yamashita T, Ario K, Komatsu T, Makita F, Shimada M, Hirashima N, Yokohama S, Nishimura H, Sugimoto R, Komura T, Ota H, Kojima M, Nakamuta M, Fujimori N, Yoshizawa K, Mano Y, Takahashi H, Hirooka K, Tsuruta S, Sato T, Yamasaki K, Kugiyama Y, Motoyoshi Y, Suehiro T, Saeki A, Matsumoto K, Nagaoka S, Abiru S, Yatsunashi H, Ito M, Kawata K, Takaki A, Arai K, Arinaga-Hino T, Abe M, Harada M, Taniai M, Zeniya M, Ohira H, Shimoda	Hepatology 80: 776-790, 2024
24 原著	Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019	Danpanichkul P, Aboona MB, Sukphutanan B, Kongarin S, Duangsonk K, Ng CH, Muthiah MD, Huang DQ, Seko Y, Díaz LA, Arab JP, Yang JD, Chen VL, Kim D, Noureddin M, Liangpunsakul S, Wijarnpreecha K	Hepatology 80: 828-843, 2024
25 原著	Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma	Suzuki H, Iwamoto H, Tanaka T, Sakaue T, Imamura Y, Masuda A, Nakamura T, Koga H, Hoshida Y, Kawaguchi T	Hepatology International 18: 610-622, 2024
26 原著	Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells	Tanaka T, Koga H, Suzuki H, Iwamoto H, Sakaue T, Masuda A, Nakamura T, Akiba J, Yano H, Torimura T, Kawaguchi T	Hepatology International 18: 984-997, 2024

27 原著	The Impact of Non-obese Metabolic Dysfunction-associated Fatty Liver Disease on Risk Factors for the Recurrence of Esophageal Squamous Cell Carcinoma Treated with Endoscopic Submucosal Dissection: A Multicenter Study	Fukunaga S, Mukasa M, Nakane T, Nakano D, Tsutsumi T, Chou T, Tanaka H, Hayashi D, Minami S, Ohuchi A, Nagata T, Takaki K, Takaki H, Miyajima I, Nouno R, Araki T, Morita T, Torimura T, Okabe Y, Kawaguchi T	Hepatology Research 54: 201-212, 2024
28 原著	Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study	Sano T, Amano K, Ide T, Isoda H, Honma Y, Morita Y, Yano Y, Nakamura H, Itano S, Miyajima I, Shirachi M, Kuwahara R, Ohno M, Kawaguchi T, Tsutsumi T, Nakano D, Arinaga-Hino T, Kawaguchi M, Eguchi Y, Torimura T, Takahashi H, Harada M, Kawaguchi T, Saks Study Group	Hepatology Research 54: 326-335, 2024
29 原著	Impact of metabolic dysfunction-associated fatty liver disease on the incidence of Helicobacter pylori-negative gastric cancer	Nakane T, Fukunaga S, Nakano D, Tsutsumi T, Tanaka H, Chou T, Minami S, Ohuchi A, Nagata T, Takaki K, Takaki H, Miyajima I, Nouno R, Yoshinaga S, Mukasa M, Okabe Y, Kawaguchi T	Hepatology Research 54: 540-550, 2024
30 原著	Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U/L, exercise habits, and metabolic dysfunction-associated steatotic liver disease	Nakano M, Kawaguchi M, Kawaguchi T, Yoshiji H	Hepatology Research 54: 655-666, 2024
31 原著	Safety and effectiveness of SARS-CoV-2 vaccines for patients with intractable hepatobiliary diseases: A multicenter, questionnaire-based, cross-sectional study	Tanifuji A, Ohfuji S, Matsumoto K, Abe M, Komori A, Takahashi A, Kawata K, Sato K, Joshita S, Umemura T, Ueno M, Nakayama N, Kakisaka K, Arinaga-Hino T, Ito K, Kanai S, Miura R, Arizumi T, Asaoka Y, Ito T, Shimizu T, Yoshida H, Ohta M, Mizuno S, Isayama H, Morimoto Y, Mochida S, Ohira H, Tanaka A	Hepatology Research 54: 706-715, 2024
32 原著	Validation study of age-independent fibrosis score (Fibrosis-3 index) in patients with metabolic dysfunction-associated steatotic liver disease	Nouso K, Kawanaka M, Fujii H, Kariyama K, Toyoda H, Iwaki M, Hayashi H, Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Kumada T, Okanou T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Hepatology Research 54: 912-920, 2024
33 原著	Evaluation of the associations of interleukin-7 genetic variants with toxicity and efficacy of immune checkpoint inhibitors: A replication study of a Japanese population, based on the findings of a European genome-wide association study	Miyamoto H, Kondo Y, Itobayashi E, Uehara M, Hiraoka A, Kudo M, Kakizaki S, Kagawa T, Miuma S, Suzuki T, Sugi K, Suyama K, Beppu T, Toyoda H, Yoshiji H, Uojima H, Miyase S, Inoue K, Tamori A, Ito T, Shimose S, Suda G, Hayashi T, Onishi M, Narahara S, Watanabe T, Iwatsuki M, Fukushima S, Tanaka Y	Hepatology Research 54: 1215-1225, 2024

34 原著	α -FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma	Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H,	International Journal of Cancer 154: 1043–1056, 2024
35 原著	A tumor endothelial cell-specific microRNA replacement therapy for hepatocellular carcinoma	Iwamoto H, Suzuki H, Masuda A, Sakaue T, Nakamura T, Tanaka T, Sakai M, Imamura Y, Yano H, Torimura T, Koga H, Yasuda K, Tsurusaki M, Seki T, Kawaguchi T	iScience 27: 108797, 2024
36 原著	Global and regional burden of alcohol-associated liver disease and alcohol use disorder in the elderly	Danpanichkul P, Suparan K, Ng CH, Dejvajara D, Kongarin S, Panpradist N, Chaiyakunapruk N, Muthiah MD, Chen VL, Huang DQ, Díaz LA, Noureddin M, Arab JP, Wijarnpreecha K	JHEP Reports 6: 101020, 2024
37 原著	The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease	Younossi ZM, AlQahtani SA, Funuyet-Salas J, Romero-Gómez M, Yilmaz Y, Keklikkiran C, Alswat K, Yu ML, Liu CJ, Fan JG, Zheng MH, Burra P, Francque SM, Castera L, Schattenberg JM, Newsome PN, Allen AM, El-Kassas M, Treeprasertsuk S, Hameed S, Wai-Sun Wong V, Zelber-Sagi S, Takahashi H, Kawaguchi T, Castellanos Fernández MI, Duseja A, Arrese M, Rinella M, Singal AK, Gordon SC, Fuchs M, Eskridge W, Alkhouiri N, Cusi K, Loomba R, Ranagan J, Kautz A, Ong JP, Kugelmas M, Eguchi Y, Diago M, Gerber L, Lam B, Fornaresio L, Nader F, Spearman CW, Roberts SK, Chan WK, Silva M, Racila A, Golabi P, Ananchuensook P, Henry L,	JHEP Reports 6: 101066, 2024
38 原著	The Global Burden of Early-Onset Biliary Tract Cancer: Insight From the Global Burden of Disease Study 2019	Danpanichkul P, Ng CH, Tan DJH, Muthiah MD, Kongarin S, Srisurapanont K, Kanjanakot Y, Duangsonk K, Huang DQ, Suzuki H, Harnois DM, Yang JD, Noureddin M, Wijarnpreecha K	Journal of Clinical and Experimental Hepatology 14: 101320, 2024
39 原著	ISG15 mediates the function of extracellular vesicles in promoting ovarian cancer progression and metastasis	Dorayappan KDP, Wagner V, Park D, Newcomer MM, Lightfoot MDS, Kalaiyarasan D, Sakaue T, Khadraoui W, Yu L, Wang QE, Maxwell GL, O'Malley D, Pollock RE, Cohn DE, Selvendiran K	Journal of Extracellular Biology 3:e92, 2024

40 原著	Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: a meta-analysis of randomized controlled trials	Kawaguchi T, Kawaguchi A, Hashida R, Nakano D, Tsutsumi T, Kawaguchi M, Koya S, Hirota K, Tomita M, Tsuchihashi J, Narao H, Matsuse H, Hiraoka K, Ejima K, Iwami S, Yoshio S	Journal of Gastroenterology 59: 216–228, 2024
41 原著	Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria	Naganuma M, Nakamura N, Kunisaki R, Matsuoka K, Yamamoto S, Kawamoto A, Saito D, Kobayashi T, Nanki K, Narimatsu K, Shiga H, Esaki M, Yoshioka S, Kato S, Saruta M, Tanaka S, Yasutomi E, Yokoyama K, Moriya K, Tsuzuki Y, Ooi M, Fujiya M, Nakazawa A, Takagi T, Omori T, Tahara T, Hisamatsu T; Japanese UC Study Group	Journal of Gastroenterology 59: 302–314, 2024
42 原著	iATT liver fat quantification for steatosis grading by referring to MRI proton density fat fraction: a multicenter study	Hirooka M, Ogawa S, Koizumi Y, Yoshida Y, Goto T, Yasuda S, Yamahira M, Tamai T, Kuromatsu R, Matsuzaki T, Suehiro T, Kamada Y, Sumida Y, Hiasa Y, Toyoda H, Kumada T	Journal of Gastroenterology 59: 504–514, 2024
43 原著	Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation	Uojima H, Yamasaki K, Sugiyama M, Kage M, Ishii N, Shirabe K, Hidaka H, Kusano C, Murakawa M, Asahina Y, Nishimura T, Iijima H, Sakamoto K, Ito K, Amano K, Kawaguchi T, Tamaki N, Kurosaki M, Suzuki T, Matsuura K, Taketomi A, Joshita S, Umemura T, Nishina S, Hino K, Toyoda H, Yatsushashi H, Mizokami M	Journal of Gastroenterology 59: 598–608, 2024
44 原著	Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials	Kawaguchi T, Murotani K, Kajiyama H, Obara H, Yamaguchi H, Toyofuku Y, Kaneko F, Seino Y, Uchida S	Journal of Gastroenterology 59: 836–848, 2024
45 原著	Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan	Kawaguchi T, Fujishima Y, Wakasugi D, Io F, Sato Y, Uchida S, Kitajima Y	Journal of Gastroenterology 59: 1120–1132, 2024
46 原著	Development and validation of a predictive scoring system for post-transarterial chemoembolization pain management in liver cancer patients	You K, Wang J, Xu J, Zhang C, Wang X, Gavrilidis P, Kawaguchi T, Wang Y	Journal of Gastrointestinal Oncology 15: 425–434, 2024

47 原著	Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease	Younossi ZM, AlQahtani SA, Alswat K, Yilmaz Y, Keklikkiran C, Funuyet-Salas J, Romero-Gómez M, Fan JG, Zheng MH, El-Kassas M, Castera L, Liu CJ, Wai-Sun Wong V, Zelber-Sagi S, Allen AM, Lam B, Treeprasertsuk S, Hameed S, Takahashi H, Kawaguchi T, Schattenberg JM, Duseja A, Newsome P, Francque S, Spearman CW, Castellanos Fernández MI, Burra P, Roberts SK, Chan WK, Arrese M, Silva M, Rinella M, Singal AK, Gordon S, Fuchs M, Alkhouri N, Cusi K, Loomba R, Ranagan J, Eskridge W, Kautz A, Ong JP, Kugelmas M, Eguchi Y, Diago M, Yu ML, Gerber L, Fornaresio L, Nader F, Henry L, Racila A, Golabi P, Stepanova M, Carrieri P, Lazarus	Journal of Hepatology 80: 419-430, 2024
48 原著	Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study	Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H,	Liver Cancer 13: 522-536, 2024
49 原著	Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"	Kudo M, Tsuchiya K, Yamashita T, Koga H, Nakagawa Y, Ikeda M	Liver Cancer 13: 671-673, 2024

50 原著	Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab	Rimini M, Stefanini B, Tada T, Suda G, Shimose S, Kudo M, Finkelmeier F, Yoo C, Presa J, Amadeo E, Genovesi V, De Grandis MC, Iavarone M, Marra F, Foschi F, Tamburini E, Rossari F, Vitiello F, Bartalini L, Soldà C, Tovoli F, Vivaldi C, Lonardi S, Silletta M, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Himmelsbach V, Montes M, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K,	Liver International 44: 1108–1125, 2024
51 原著	Rising global burden of cancer attributable to high BMI from 2010 to 2019	Tan DJH, Ng CH, Muthiah M, Yong JN, Chee D, Teng M, Wong ZY, Zeng RW, Chin YH, Wang JW, Danpanichkul P, Rajaram RB, DasGupta R, Suzuki H, Takahashi H, Tamaki N, Dan YY, Lui R, Duseja A, Siddiqui MS, Yeoh KG, Sanyal A, Wijarnpreecha K, Loomba R, Mantzoros CS, Huang DQ	Metabolism : clinical and experimental 152: 155744, 2024
52 原著	Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: systematic analysis from the global burden of disease study 2019	Danpanichkul P, Suparan K, Dutta P, Kaeosri C, Sukphutanan B, Pang Y, Kulthamongsri N, Jaisa-Aad M, Ng CH, Teng M, Nakano M, Morishita A, Alkhoury N, Yang JD, Chen VL, Kim D, Fallon MB, Diaz LA, Arab JP, Mantzoros CS, Nouredin M, Lazarus JV, Wijarnpreecha K	Metabolism : clinical and experimental 158: 155958, 2024
53 原著	Comparative efficacy of THR- β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis	Lin RT, Sun QM, Xin X, Ng CH, Valenti L, Hu YY, Zheng MH, Feng Q	Metabolism : clinical and experimental 161: 156043, 2024
54 原著	Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin	Sakaue T, Dorayappan KDP, Zingarelli R, Khadraoui W, Anbalagan M, Wallbillich J, Bogner B, Wanner R, Cosgrove C, Suarez A, Koga H, Maxwell GL, O'Malley DM, Cohn DE, Selvendiran K	Oncogene 43: 3586–3597, 2024
55 原著	Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real-world practice	Shimose S, Saeki I, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Naganuma A, Nishina S, Otsuka M, Kawashima H, Takayama T, Takami T, Kawaguchi T	Oncology Letters 28: 397, 2024

56 原著	Efficacy of timing-dependent infusion of nivolumab in patients with advanced gastric cancer	Tanaka T, Suzuki H, Yamaguchi S, Shimotsuura Y, Nagasu S, Murotani K, Fujita F, Kawaguchi T, Miwa K	Oncology Letters 28: 463, 2024
57 原著	Patient Satisfaction Survey on Portable Infusion Pumps for Colorectal Cancer Chemotherapy: Hard-Shelled or Soft-Shelled?	Yamada T, Kikuchi T, Nagasu S, Hashimoto K, Furukawa E, Matsumoto H, Tsutsumi K, Tanaka T, Kugishima M, Kawaguchi T, Fujita F, Higuchi K, Miwa K	Patient Preference and Adherence 18: 1443-1449, 2024
58 原著	Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy	Saeki I, Shimose S, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Kanayama Y, Naganuma A, Nishina S, Otsuka M, Kobara H, Kawashima H, Takayama T, Kawaguchi T, Yamasaki T, Takami T; Hepatology InVestigator Experts in Japan (HIVE-J) Study Group	PLoS One 19: e0311084, 2024
59 原著	Persistence of newly prescribed 5-aminosalicylic acid in patients with ulcerative colitis: A nationwide comprehensive database study	Noda T, Kuwaki K, Machida M, Okumura Y, Nishioka Y, Myojin T, Imamura T	PLoS One 19: e0316181, 2024
60 原著	Hepatic arterial infusion of autologous CD34+ cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial	Nakamura T, Masuda A, Kako M, Enomoto H, Kaibori M, Fujita Y, Tanizawa K, Ioji T, Fujimori Y, Fukami K, Hazama T, Iwamoto H, Kako Y, Kobayashi K, Koga H, Nagafuji K, Ohtake T, Suzuki H, Takashima T, Tsukiyama T, Uojima H, Yamahara K, Yamakado K, Yamamoto H, Yoh K, Yoshihara S, Kawamoto A, Nishiguchi S, Kobayashi S, Torimura T, Kawaguchi T	Regenerative Therapy 27: 455-463, 2024
61 原著	Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel	Shibuki T, Otsuka T, Shimokawa M, Nakazawa J, Arima S, Fukahori M, Miwa K, Okabe Y, Koga F, Ueda Y, Kubotsu Y, Makiyama A, Shimokawa H, Takeshita S, Nishikawa K, Komori A, Otsu S, Hosokawa A, Sakai T, Oda H, Kawahira M, Arita S, Honda T, Taguchi H, Tsuneyoshi K, Kawaguchi Y, Fujita T, Sakae T, Nio K, Ide Y, Ureshino N, Shirakawa T, Mizuta T, Mitsugi K	Scientific Reports 14: 16906, 2024

62 原著	Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab	Rimini M, Montes M, Amadeo E, Vitiello F, Kudo M, Tada T, Suda G, Shimose S, Lonardi S, Finkelmeier F, Salani F, Antonuzzo L, Marra F, Iavarone M, Cabibbo G, Foschi FG, Silletta M, Sacco R, Rapposelli IG, Scartozzi M, Nicoletta P, Aldrighetti L, Persano M, Camera S, Rossari F, Foti S, Kumada T, Hiraoka A, Iwamoto H, Rizzato MD, Himmelsbach V, Masi G, Corradi M, Celsa C, Fabio C, Frassinetti GL, Cascinu S, Casadei-Gardini A, Presa J	Scientific Reports 14: 20200, 2024
63 原著	Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab	Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano	Targeted Oncology 19: 645–659, 2024
64 原著	Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma	Camera S, Rimini M, Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Salani F, Marseglia M, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Lonardi S, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano	Targeted Oncology 19: 29–39, 2024
65 原著	From Shadows to Spotlight: Exploring the Escalating Burden of Alcohol-Associated Liver Disease and Alcohol Use Disorder in Young Women	Danpanichkul P, Ng CH, Muthiah M, Suparan K, Hao Tan DJ, Duangsonk K, Sukphutanan B, Kongarin S, Harinwan N, Panpradist N, Takahashi H, Kawaguchi T, Vichitkunakorn P, Chaiyakunapruk N, Nathisuwan S, Huang D, Arab JP, Noureddin M, Mellinger JL, Wijarnpreecha K	The American Journal of Gastroenterology 119: 893–909, 2024

66 原著	Sex-based Disparities in Liver Transplantation for Hepatocellular Carcinoma and the Impact of the Growing Burden of NASH	Koh JH, Chee D, Ng CH, Wijarnpreecha K, Muthiah M, Tan DJH, Lim WH, Zeng RW, Koh B, Xuan ETX, Bonney G, Iyer S, Young DY, Nakamura T, Takahashi H, Noureddin M, Siddiqui MS, Simon TG, Loomba R, Huang DQ	Transplantation Direct 10: e1642, 2024
67 症例報告	Successful endoscopic retrieval of migrated biliary plastic stent via hepaticogastrostomy route using uneven double-lumen catheter and stent retriever	Hirai S, Okabe Y, Yoshioka S	Digestive Endoscopy 36: 959-960, 2024
68 症例報告	A Significant Increase in the Serum Carbohydrate Antigen 19-9 Level Accompanied by Acute Cholecystitis and Choledocholithiasis: A Case Report and Review of the Literature	Kawaguchi T, Araki Y, Kajiwara A, Nakao K, Sakakibara S, Sasaki Y, Aino H, Maekawa R, Okabe Y, Kawaguchi T	Internal Medicine 63: 1713-1718, 2024
69 症例報告	肝細胞癌に対するatezolizumab＋bevacizumab併用療法後に出現した下垂体性副腎皮質機能低下症の3症例	森山悦子、岩本英希、新関 敬、永山綾子、城野智毅、下瀬茂男、中野聖士、野田悠、鈴木浩之、酒井味和、黒松亮子、古賀浩徳、野村政壽、川口 巧	肝臓 65: 37-44, 2024
70 症例報告	MASLD/MASH関連肝硬変を背景に脂肪肝炎様肝細胞癌を発症した43歳高度肥満症の1例	川口俊弘、下瀬茂男、近藤礼一郎、佐藤寿洋、久下 亨、矢野博久、川口 巧	肝臓 65: 131-138, 2024
71 症例報告	造影超音波検査の肝細胞癌非特異的所見により切除を回避し得た肝血管筋脂肪腫の1例	楠美雅陸、中野聖士、中村 徹、水落伸治、増田篤高、鈴木浩之、新関 敬、岩本英希、下瀬茂男、城野智毅、野田 悠、森山悦子、秋葉 純、黒松亮子、古賀浩徳、川口 巧	肝臓 65: 223-230, 2024
72 症例報告	リハビリテーション治療によりフレイルが改善したアルコール性非代償性肝硬変の1症例	神谷俊次、中野 暖、服部優依、永松あゆ、戸次鎮宗、佐野有哉、天野恵介、川口真知子、園田ルミ子、岡田晃代、松瀬博夫、川口 巧	肝臓 65: 559-565, 2024
73 症例報告	腹部から頸部までの連続するアプローチとその総合評価が有用であった食道アカラシアの1症例	福井智一、鈴木浩之、高田晃男、坂口ちなつ、内田祐介、三堂広樹、峰松峰佳、森田俊、川口 巧	超音波検査技術 49: 391-396, 2024
74 総説	Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis	Lim WH, Tay P, Ng CH, Tan DJH, Ong C, Koh JH, Teng M, Chee D, Wong ZY, Kawaguchi T, Takahashi H, Muthiah M, Tan EXX, Wijarnpreecha K, Lee GH, Noureddin M, Lee BP, Mathurin P, Loomba R, Huang DQ	Alimentary Pharmacology & Therapeutics 59: 730-741, 2024
75 総説	Global prevalence, clinical characteristics, surveillance, treatment allocation, and outcomes of alcohol-associated hepatocellular carcinoma	Zeng RW, Ong CEY, Ong EYH, Chung CH, Lim WH, Xiao J, Danpanichkul P, Law JH, Syn N, Chee D, Kow AWC, Lee SW, Takahashi H, Kawaguchi T, Tamaki N, Dan YY, Nakajima A, Wijarnpreecha K, Muthiah MD, Noureddin M, Loomba R, Ioannou GN, Tan DJH, Ng CH, Huang DQ	Clinical Gastroenterology and Hepatology 22: 2394-2402, 2024

76 総説	Alcohol and Metabolic Syndrome Interaction	Hashida R, Golabi P, Ong J, Kawaguchi T, Younossi ZM	Clinics in Liver Disease 28: 601-620, 2024
77 総説	Association between nonalcoholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication	Sakaue T, Terabe H, Takedatsu H, Kawaguchi T	Hepatology Research 54: 729-735, 2024
78 総説	Guidelines for the diagnosis and treatment of idiopathic portal hypertension, extrahepatic portal obstruction, and Budd-Chiari syndrome in Japan	Furuichi Y, Kage M, Ohta M, Ohfuji S, Sasaki H, Hidaka H, Yoshida H, Kanto T, Kusano H, Akahoshi T, Obara K, Hashizume M, Kuniyoshi Y, Kawaguchi T, Okubo H, Ishikawa T, Hirooka M, Iwakiri Y, Nio M, Tanaka A	Hepatology Research 54: 952-969, 2024
79 総説	NAFLD and NAFLD-related HCC in Asia: Burden and Surveillance	Koh JH, Wang M, Suzuki H, Muthiah M, Ng CH, Huang DQ	Journal of Clinical and Experimental Hepatology 14: 101213, 2024
80 総説	Ultrasonographic Assessment of Tissue Stiffness: Recent Progress in Transient Elastography and Shear Wave Elastography in the Liver and Various Organs	Nakano M, Kuromatsu R, Kawaguchi T	The Kurume Medical Journal 70: 1-10, 2024
81 総説	特集 肥満症とやせの問題 セミナー 適正な体重管理を促すための心得 脂肪性肝疾患にどう向き合うか	中村 徹、川口 巧	Medical Practice 41: 1844-1851, 2024
82 総説	MetALDの実態と肝病理所見	川口 巧、藤井英樹、岩城慶大、米田正人、川中美和	アルコールと医学生物学 Vol. 43 43: 8-10, 2024
83 総説	特集 MASLD/MASH-脂肪性肝疾患の新概念- 1.疾患概念オーバービュー: MASLD/MASHとは?	鈴木浩之、堤 翼、佐野有哉、天野恵介、中野 暖、福永秀平、田中俊光、中野聖士、川口 巧	肝臓クリニカルアップデート 10: 6-12, 2024
84 総説	特集 チーム医療で取り組む肝胆膵疾患の栄養マネジメント II.各論: 肝臓 非アルコール性脂肪性肝疾患患者の栄養管理とヘパトサイズ	佐野有哉、中野 暖、堤 翼、天野恵介、橋田竜騎、松瀬博夫、平岡弘二、川口 巧	肝胆膵 88: 65-70, 2024
85 総説	MASLD/MASHに対する栄養・運動療法	佐野有哉、戸次鎮宗、川口 巧	週刊 医学のあゆみ 289: 392-397, 2024
86 総説	脂肪肝の新基準MASLDと運動療法: 肝炎体操とヘパトサイズ	川口 巧	消化と吸収 46: 91-94, 2024
87 総説	特集 消化管静脈瘤診療Update [内視鏡医が知っておきたい門脈圧亢進症診療] IVRによる消化管静脈瘤治療	井上博人、於保和彦、久永 宏	消化器内視鏡 36: 1722-1726, 2024
88 総説	特集 肝疾患診療の進歩 腸内細菌と肝疾患	川口 巧、中野聖士、中村 徹	日本医師会雑誌 153: 850, 2024

89 総説	特集 / 日常診療での超音波検査の おさえどころ 超音波検査の最 近の進歩 肝の造影超音波検査	黒松亮子	臨牀と研究 101: 829-835, 2024
90 総説	特集 サルコペニアと消化器疾患 1 サルコペニア総論 (5)肝疾患におけるサルコペニアの 予防・治療	中野 暖、佐野有哉、堤 翼、天野恵介、川 口 巧	臨牀消化器内科 39:263-270, 2024
91 総説	特集 脂肪肝の新概念:MASLD 1.日本人MASLDのNatural History	堤 翼、鈴木浩之、福永秀平、中野聖士、 中野 暖、川口 巧	臨牀消化器内科 39:736-741, 2024
92 総説	特集 脂肪肝の新概念:MASLD 5.MASLDの画像診断 (1)MASLDの 超音波	中野聖士、川口真知子、水島靖子、黒松亮 子、内藤嘉紀、川口 巧	臨牀消化器内科 39:779-784, 2024
93 Editorial	Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on "Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis"	Nakamura T, Nakano M, Tsutsumi T, Amano K, Kawaguchi T	Clinical and Molecular Hepatology 30: 705-708, 2024
94 Editorial	人工知能がもたらす肝胆膵疾患の 未来	岡部義信	BIO Clinica 39: 1, 2024
95 Letter	Changing from NAFLD to MASLD: Similar Cumulative Incidence of Reflux Esophagitis between NAFLD and MASLD	Fukunaga S, Mukasa M, Nakano D, Tsutsumi T, Kawaguchi T	Clinical and Molecular Hepatology 30: 121-123, 2024
96 Letter	Changing from NAFLD to MASLD: Similar Prognosis of Patients with HCC Under Atezo/Bev treatment between NAFLD and MASLD	Suzuki H, Shimose S, Iwamoto H, Niizeki T, Kawaguchi T	Clinical and Molecular Hepatology 30: 263-265, 2024
97 Letter	Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease	Tsutsumi T, Nakano D, Kawaguchi M, Takahashi H, Kawaguchi T	Clinical and Molecular Hepatology 30: 266-268, 2024
98 Letter	Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia	Suzuki H, Tsutsumi T, Kawaguchi M, Amano K, Kawaguchi T	Clinical and Molecular Hepatology 30: 577-579, 2024
99 Letter	Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia	Fukunaga S, Nakane T, Mukasa M, Takedatsu H, Kawaguchi T	Clinical and Molecular Hepatology 30: 959-961, 2024

100 Letter	Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease	Suzuki H, Tsutsumi T, Kawaguchi M, Amano K, Kawaguchi T	Clinical and Molecular Hepatology 30: 962-964, 2024
101 Letter	The Global Burden of Alcohol-associated Cirrhosis and Cancer in Young and Middle-aged Adults	Danpanichkul P, Ng CH, Hao Tan DJ, Wijarnpreecha K, Huang DQ, Noureddin M; Young Alcohol Disease Collaborative (Sano T)	Clinical Gastroenterology and Hepatology 22: 1947-1949, 2024
102 Letter	The Immune Inductive Role of Hepatic Arterial Infusion Chemotherapy Prior to Atezolizumab Plus Bevacizumab Combination Therapy in Hepatocellular Carcinoma	Suzuki H, Sakai M, Iwamoto H, Shimose S, Niizeki T, Nakano M, Shirono T, Noda Y, Moriyama E, Kuromatsu R, Koga H, Kawaguchi T	Gastro Hep Advances 3: 506-509, 2024
103 Letter	Changing from NAFLD to MASLD: Similar Prognosis of Unresectable Extrahepatic Gastrointestinal Cancer Under Chemotherapy between NAFLD and MASLD	Suzuki H, Tanaka T, Yamaguchi S, Miwa K, Kawaguchi T	Journal of Hepatology 80: e150-e151, 2024
104 Letter	Almost Identical Values of Various Noninvasive Indexes for Hepatic Fibrosis and Steatosis between NAFLD and MASLD in Asia	Nakano M, Kawaguchi M, Kawaguchi T	Journal of Hepatology 80: e155-e157, 2024
105 Letter	Letter: Changing from NAFLD to MASLD: The Implications for health related quality of life data	Hashida R, Nakano D, Kawaguchi M, Younossi ZM, Kawaguchi T	Journal of Hepatology 80: e249-e251, 2024
106 Letter	Impact of the MetALD terminology on the prevalence of alcohol-related fatty liver disease in US adults (2017-2020)	Fouad Y, Kawaguchi T, Yilmaz Y	Liver International 44: 3112-3113, 2024
107 報告書	Impact of Lesion Location on Recurrence After Resection of T1 Colorectal Cancer: Post Hoc Analysis of a Nationwide Multicenter Cohort Study	Minamide T, Ikematsu H, Kajiwara Y, Oka S, Ajioka Y, Ueno H; Japanese Society for Cancer of the Colon and Rectum (Ohuchi A)	Gastroenterology 166: 198-201, 2024
108 短報	Diagnostic performance of shear wave measurement in the detection of hepatic fibrosis: A multicenter prospective study	Kumada T, Toyoda H, Ogawa S, Gotoh T, Yoshida Y, Yamahira M, Hirooka M, Koizumi Y, Hiasa Y, Tamai T, Kuromatsu R, Matsuzaki T, Suehiro T, Kamada Y, Sumida Y, Tanaka J, Shimizu M	Hepatology Research 54: 851-858, 2024
109 短報	The Burden of Overweight and Obesity-Associated Gastrointestinal Cancers in Low and Lower-Middle-Income Countries: A Global Burden of Disease 2019 Analysis	Danpanichkul P, Auttapracha T, Sukphutanan B, Ng CH, Wattanachayakul P, Kongarin S, Dutta P, Duangsonk K, Thongpiya J, Muthiah MD, Huang DQ, Lui RN, Seko Y, Takahashi H, Noureddin M, Yang JD, Wallace MB, Wijarnpreecha K	The American Journal of Gastroenterology 119: 1177-1180, 2024

110 短報	奈良宣言 (ALT over 30) のMASLD (metabolic dysfunction-associated steatotic liver disease) における臨床的意義の検証	川中美和、藤井英樹、岩城慶大、林 秀樹、豊田秀徳、大枝 敏、兵庫秀幸、森下朝洋、宗景玄祐、川田一仁、堤 翼、澤田康司、前城達次、飛田博史、吉田雄一、内藤雅文、荒木亜寿香、新垣伸吾、川口巧、則武秀尚、小野正文、正木 勉、安田諭、富田栄一、米田正人、徳重明央、鎌田佳宏、高橋宏和、植田真一郎、相島慎一、角田圭雄、岡上 武、中島 淳、Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	肝臓 65: 186-191, 2024
111 座談会	〈特集〉座談会 肝臓リハビリテーションの現状と問題点	寺井崇二、吉治仁志、川口 巧、清水雅仁、辻 哲也	肝臓 65: 351-367, 2024
112 その他	Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol	Iwaki M, Kobayashi T, Nogami A, Ogawa Y, Imajo K, Sakai E, Nakada Y, Koyama S, Kurihashi T, Oza N, Kohira T, Okada M, Yamaguchi Y, Iwane S, Kageyama F, Sasada Y, Matsushita M, Tadauchi A, Murohisa G, Nagasawa M, Sato S, Maeda K, Furuta K, Shigefuku R, Seko Y, Tobita H, Kawata K, Kawanaka M, Sugihara T, Tamaki N, Iwasa M, Kawaguchi T, Itoh Y, Kawaguchi A, Takahashi H, Nakajima A, Yoneda M	BMJ Open 14: e088862, 2024
113 その他	Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel	Shirakawa T, Makiyama A, Shimokawa M, Otsuka T, Shinohara Y, Koga F, Ueda Y, Nakazawa J, Otsu S, Komori A, Arima S, Fukahori M, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Akashi K, Baba E	Scientific Reports 14: 5311, 2024
114 その他	Utility of abdominal ultrasound in the preoperative diagnosis of appendiceal goblet cell adenocarcinoma	Fukui T, Suzuki H, Tanikawa K, Takata A, Sakaguchi C, Uchida Y, Sandou H, Minematsu M, Ogata S, Kawaguchi T	The American Journal of Gastroenterology 119: 611-612, 2024
115 その他	IBD注目のKey論文(133) 抗生物質使用による年齢別のIBD発症リスクについて：人口ベースのコホート研究	竹田津英稔	IBD Research 18: 141, 2024
116 その他	肝臓専門医が教える らくらく簡単トレーニング	川口 巧、高橋宏和	べんちのーと 第133号 34:18, 2024
117 その他	肝臓専門医が教える らくらく簡単トレーニング	川口 巧、高橋宏和	べんちのーと 第134号 35:18, 2024
118 その他	肝臓専門医が教える らくらく簡単トレーニング	川口 巧、高橋宏和	べんちのーと 第135号 35:18, 2024
119 その他	肝臓専門医が教える らくらく簡単トレーニング	川口 巧、高橋宏和	べんちのーと 第136号 35:18, 2024

2024年 著書・論文 P. 17

120 その他	定期の健康診断からわかる動脈硬化性疾患と脂肪肝のリスク評価	伊藤 実	修親 66-70, 2024
121 その他	連載: Key Word 77:TL1A	竹田津英稔	消化器病学サイエンス 8: 2, 2024
122 その他	脂肪肝のCOPD発症におけるミオスタチンの生物学的作用機序の解明	堤 翼	第16回 ふくおか「臨床医学研究賞」業績集 p.19-20, 2024
123 その他	特集 脂肪肝の新概念:MASLD 巻頭言 一本特集を企画するにあたって-	川口 巧	臨牀消化器内科 39:733-735, 2024
124 その他	肝炎体操で脂肪肝に克つ!	川口 巧	COCORO 2024 Spring 7:13, 2024
125 その他(E-Videos)	Endoscopic hand-suturing training model	Morita T, Ohata K, Araki T, Koda M, Fukumori K, Minato Y, Kawaguchi T	Endoscopy 56: E299-E300, 2024
126 その他(E-Videos)	Novel endoscopic approach for safe and effective resection of duodenal neuroendocrine tumor	Minami S, Fukunaga S, Mukasa M, Ohzono D, Tanaka H, Nakane T, Takedatsu H	Endoscopy 56: E961-E962, 2024
127 その他(メディア)	改訂版・肝臓★肝ケア&脂肪肝に効く運動大幅追加!	川口 巧	NHK あしたが変わるトリセツショー 2024.12.5
128 その他(メディア)	インタビュー	川口 巧	Tarzan 2024.12.12
129 その他(メディア)	【ALT30啓発企画】沈黙の臓器「肝臓」血液検査でALT値が30を超えたら早期に受診を	川口 巧	朝日新聞西部本社版朝刊 2024.7.28